Contact Us
Drug Search Results
More Filters [+]

Duodopa

Alternative Names: duodopa, dm-1992, dm1992, dm 1992, ipx-066, ipx066, ipx 066, nd-0612, nd0612, nd 0612
Latest Update: 2024-06-25
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DDC Inhibitor,DR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Croatia | Cyprus | Czech | Denmark | Estonia | France | Germany | Hungary | India | Italy | Japan | Lithuania | New Zealand | Norway | Pakistan | Poland | Portugal | Russia | Slovakia | South Africa | Spain | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: NeuroDerm
Company Location: REHOVOT L3 7670203
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Duodopa

Countries in Clinic: Austria, Belgium, Czech Republic, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Portugal, Russia, Slovakia, Spain, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ND0612H-012

P2

Not yet recruiting

Parkinson's Disease

2027-05-23

ND0612-317

P3

Not yet recruiting

Parkinson's Disease

2027-05-06

2015-005814-31

P2

Active, not recruiting

Parkinson's Disease

2025-02-28

BouNDless

P3

Active, not recruiting

Parkinson's Disease

2023-05-18

Recent News Events

Date

Type

Title

05/01/2024

PubMed

 Effect of levodopa on pathological gait in Dravet syndrome: A randomized crossover trial using three-dimensional gait analysis.

05/01/2024

PubMed

 Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.

02/08/2024

News Article

 AbbVie's VYALEV™ (foslevodopa/foscarbidopa solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

09/07/2022

News Article

 Dizlin Pharmaceuticals publishes data from pharmacokinetic study (PK) (IPO-001) with Infudopa SubC (DIZ102) and Infudopa IntraV (DIZ101) in Neurology

09/10/2021

News Article

 AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021

09/11/2020

News Article

 AbbVie to Present New Data From 18 Abstracts at the International Congress of Parkinson's Disease and Movement Disorders®

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions